Logo
Login
$ZVRA
$9.53 -$0.28 (2.85%) Close

Company Executives

$ZVRA Management Team

Mr. R. LaDuane Clifton

Chief Financial Officer

Treasurer

Age 52
Compensation $1.450M USD
Sex Male

Ms. Tamara Favorito

Independent Chairman of the Board

Age 66
Compensation $365.0K USD
Sex Female

Mr. Joshua Schafer

Executive Vice President - Business Development

Chief Commercial Officer

Age 54
Compensation $1.815M USD
Sex Male

Dr. Adrian Quartel

Chief Medical Officer

Age 64
Compensation $2.515M USD
Sex Male

Mr. Rahsaan Thompson

Chief Legal Officer

Secretary

Compliance Officer

Age 53
Compensation -
Sex Male

Mr. Neil Mcfarlane

President

Chief Executive Officer

Director

Age 52
Compensation $5.355M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 20, 2026
Directors
8
serving now
Independent
7 of 8
stated in the proxy
Average tenure
2.9 years
from year joined
CEO also chairs the board
No
Tamara A. Favorito
Director Age On board Independent Committees Other public boards 2025 pay Source
Douglas W. Calder
59 2023
3 years
 Independent None stated None stated $243,992
Corey Watton
56 2023
3 years
 Independent
Audit Compensation
None stated $249,678
Alicia Secor
63 2025
1 year
 Independent
Audit Compensation
None stated Not stated
Tamara A. Favorito
Board chair
 67 2021
5 years
 Independent
Audit · Chair
Artelo Biosciences, Inc. $304,678
Thomas D. Anderson
70 2023
3 years
 Independent
Compensation · Chair Nominating and Corporate Governance
None stated $252,178
Neil F. McFarlane
CEO
 53 2023
3 years
 Not independent None stated None stated Paid as CEO
Alvin Shih, M.D.
49 2024
2 years
 Independent
Compensation Nominating and Corporate Governance
None stated $244,678
Bode
Not stated Not stated Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 20, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans